Psychedelic Alpha
The leading independent publication tracking psychedelic industry business, regulatory, and policy developments — essential reading for anyone in the professional psychedelic space.
Type: Online Publication
Location: Online (UK-based)
Members: 10,000+ newsletter subscribers
Membership: Free newsletter + paid subscriber tier
Activities: ['industry news', 'policy analysis', 'market research', 'regulatory tracking', 'investor briefings']
About
Psychedelic Alpha is an independent digital publication founded by Josh Hardman focused on the business, regulatory, and policy dimensions of the psychedelic medicine industry. Published from the UK with global coverage, Psychedelic Alpha fills a critical gap between scientific journals and lay media: it covers company announcements, FDA and EMA regulatory filings, clinical trial updates, investor activity, and policy developments with a level of specificity that professionals in the field depend on.
The publication is known for its careful sourcing, willingness to report critically on industry failures and hype, and its ability to parse regulatory documents in ways that make them comprehensible to non-lawyers. Its newsletter is among the most-read industry briefings in the psychedelic space. Psychedelic Alpha also publishes longer-form analysis pieces and maintains a database of psychedelic company pipeline data.
Unlike advocacy-focused publications that tend toward optimism about the field's trajectory, Psychedelic Alpha is analytically neutral — covering setbacks like the FDA's rejection of MAPS's MDMA therapy application with the same rigor as positive developments. This editorial stance has made it a trusted source across the industry, from researchers to investors to regulators.
Why It Matters
Psychedelic Alpha is the closest thing the psychedelic industry has to a trade journal of record. For anyone tracking the business and regulatory environment around psilocybin medicine, it is indispensable.
